Cochrane · systematic review · CD008980
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Bruins Slot, KMH, Berge, E · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 40%High 3 · 60%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyComparison
Population: people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Stroke and other systemic embolic events | OR 0.89 [0.82, 0.97] | 13 studies · 67477 participants | High |
All strokes | OR 0.89 [0.81, 0.97] | 13 studies · 67449 participants | High |
Major bleedings | OR 0.78 [0.73, 0.84] | 13 studies · 67396 participants | Moderate Downgraded: inconsistency |
Intracranial haemorrhages | OR 0.5 [0.42, 0.59] | 12 studies · 66259 participants | High |
All‐cause deaths | OR 0.89 [0.83, 0.95] | 10 studies · 65624 participants | Moderate Downgraded: inconsistency |
Comparison
Population: Patients with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Stroke and other systemic embolic events ( | RR 0.82 [0.73, 0.91] | 9 studies · 40777 participants | High |
All strokes ( | RR 0.79 [0.69, 0.89] | 9 studies · 40749 participants | High |
Major bleedings ( | RR 0.9 [0.82, 0.98] | 10 studies · 42078 participants | Moderate Downgraded: inconsistency |
Intracranial haemorrhages ( | RR 0.56 [0.45, 0.7] | 8 studies · 39638 participants | High |
All‐cause deaths ( | RR 0.89 [0.82, 0.97] | 6 studies · 38924 participants | High |